In a major breakthrough that could lead to potential treatment for Down's syndrome, a team of American gene scientists claimed that they have found a way through which they were able to switch off the rouge chromosome responsible for the condition in lab-dish cells.
The breakthrough opens up the tantalising goal of therapy for Down's, they said, cautioning that years of work lie ahead before this aim is reached -- if, in fact, it is attainable.
Down's syndrome is the world's leading genetically caused mental disease, accounting for around one in 600 live births in the United States.
It also carries with it a heightened risk of heart defects, leukaemia, immune-system malfunction and premature Alzheimer's disease.
The disease, formally called trisomy 21, is caused by an additional chromosome 21, which has a cascade of unexplained impacts on brain development and body function.
Acting on a hunch, scientists at the University of Massachusetts Medical School reported that they had inserted a gene into this unwanted third chromosome and, in effect, used it like an off switch.
It is the first time that correction has been achieved for an entire chromosome, a coil of DNA that is studded with hundreds of genes, the protein-making codes to build and sustain life.
"Our hope is that for individuals living with Down's syndrome this proof-of-principle opens up multiple exciting new avenues for studying the disorder now, and brings into the realm of consideration research on the concept of 'chromosome therapy' in the future," said Jeanne Lawrence, a professor of cell and developmental biology.
People without Down's are born with 23 pairs of chromosomes, including two sex chromosomes, which pair up as two X chromosomes for females and an X and Y chromosome for males.
The team noted that, in early female embryos, a special gene called XIST comes into play, silencing one of the two X chromosomes so that they do not over-function.
Their bet, published in the journal Nature, was whether XIST could be slotted into the third, unwanted chromosome 21 in cells from a person with Down's.
The research was carried out from so-called induced pluripotent stemcells, or cells that have been reprogrammed to their versatile infant state.
Delighted with the chromosome silencing they saw in a lab dish, Lawrence's team have now started to test the technique on mice genetically modified to have trisomy 21.
The results should be known "hopefully within a year", Lawrence said in a phone interview with AFP.
Tests on lab animals are an early part of the long process of assessing a new drug or process to see if it is safe and effective for humans.
Lawrence readily acknowledged that what happens with mice may not be the same in humans, but said a conceptual logjam about chromosome therapy had at last been broken.
"I think that the importance of this work is that it now makes it conceivable -- not that we know that it will work or that it won't be a long way off, because there are a lot of questions and a lot of steps to be met," she said.
Gene therapy aims at fixing inherited diseases by substituting flawed genes with functioning ones.
After more than a decade of frustrations and setbacks, this high-risk field is now coming to fruition.
But so far, the advances are only in diseases caused by single-gene defects, not by multiple genes or a whole chromosome, which are far more complex, Lawrence said.
The greatest benefit of the work could be its contribution to a basic understanding of how trisomy 21 disrupts cells, she said.
If scientists can figure out at least some of the pathways, this opens up options for drugs that can block some of the ill effects of Down's.
"There are different severities of Down's syndrome," she said.
"There are a lot of people with Down's syndrome who are really near the threshold of being able to lead an independent life or hold down a job, and there are things that may be able to help them to achieve it."